# OnCo record limertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/limertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "limertinib" ;
  schema:name "Limertinib"@en ;
  schema:description "Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use."@en ;
  schema:url <https://onco.cc/drugs/limertinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=ASK120067> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral third-generation EGFR tyrosine kinase inhibitor" ;
  onco:approval "CN 2024: Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/aosaikang-pharmaceutical/> ;
  onco:trials <https://onco.cc/trials/nct04143607/>, <https://onco.cc/trials/nct07109531/> .